Altium Capital Management LP purchased a new stake in shares of Galera Therapeutics, Inc. (NASDAQ:GRTX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 219,900 shares of the company’s stock, valued at approximately $2,162,000. Altium Capital Management LP owned approximately 0.83% of Galera Therapeutics at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. UBS Group AG lifted its holdings in Galera Therapeutics by 122.3% during the first quarter. UBS Group AG now owns 4,349 shares of the company’s stock valued at $38,000 after purchasing an additional 2,393 shares in the last quarter. US Bancorp DE purchased a new position in Galera Therapeutics during the second quarter valued at approximately $104,000. Trexquant Investment LP purchased a new position in Galera Therapeutics during the second quarter valued at approximately $110,000. Jump Financial LLC purchased a new position in Galera Therapeutics during the second quarter valued at approximately $177,000. Finally, Panagora Asset Management Inc. lifted its holdings in Galera Therapeutics by 7.2% during the first quarter. Panagora Asset Management Inc. now owns 36,144 shares of the company’s stock valued at $319,000 after purchasing an additional 2,413 shares in the last quarter. 75.45% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have recently commented on the stock. Zacks Investment Research cut shares of Galera Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 20th. BTIG Research reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Galera Therapeutics in a research note on Sunday, September 26th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Galera Therapeutics in a report on Friday, September 24th.
Galera Therapeutics (NASDAQ:GRTX) last issued its quarterly earnings data on Tuesday, August 10th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.11). Analysts anticipate that Galera Therapeutics, Inc. will post -3.12 earnings per share for the current fiscal year.
About Galera Therapeutics
Galera Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease.
Featured Article: What are the components of an earnings report?
Want to see what other hedge funds are holding GRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Galera Therapeutics, Inc. (NASDAQ:GRTX).
Receive News & Ratings for Galera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.